RMC-6291
CAS:2641998-63-0
品牌:MedChemExpress (MCE)
存储条件:Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
生物活性:RMC-6291 是一种口服有效的 KRASG12C(ON) 共价抑制剂。RMC-6291 在 KRASG12C(ON) 和亲环蛋白 A (CypA) 之间的肿瘤细胞内形成三复合物。因此,RMC-6291 通过空间阻断 RAS 效应子结合来阻止 KRASG12C(ON) 发出信号。RMC-6291 在 KRASG12C 肿瘤模型中对 RAS 通路活性产生了深度和持久抑制。
体内:RMC-6291 (200mg/kg, 口服, 每日一次, 60天) 在小鼠肿瘤模型中显著抑制肿瘤生长并诱导免疫记忆[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Clinical Trial
参考文献:
[1]. Nichols R J, et al. RMC-6291, a next-generation tri-complex KRASG12C (ON) inhibitor, outperforms KRASG12C (OFF) inhibitors in preclinical models of KRASG12C cancers[J]. Cancer Research, 2022, 82(12_Supplement): 3595-3595.